Edouard Fu, PhD student at the Department of Clinical Epidemiology at the LUMC, uses big data to study the effectiveness and safety of kidney, diabetes and heart failure treatments. With a Rubicon grant from NWO, Edouard will conduct further research at Harvard Medical School over the next two years.
In the first round of Rubicon 2021, a total of 24 newly graduated scientists were selected to conduct research abroad at prestigious institutions such as Oxford and Harvard.
Wonder drugs for diabetics?
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new group of medications used for treating patients with type 2 diabetes, kidney disease, or heart failure. The potential impact of this novel medication class is enormous: type 2 diabetes currently affects more than 400 million people worldwide, whereas heart failure is the leading cause of hospitalizations in the Western world.
Considered a breakthrough in the treatment of diabetes and heart failure, Edouard Fu – however – highlights that initial clinical trials on the effectiveness and safety of SGLT2 inhibitors do not portray the whole picture quite yet. “These trials included very selective patient populations and their study size and duration is often not sufficient to investigate rare – but potentially serious safety outcomes. By applying cutting-edge statistical methods to big data of more than 200 million patients, we will be able to investigate the effectiveness and safety of these drugs in patients with diabetes and heart failure in a real-life setting.”
On April 15th, LUMC Global and the LUMC’s Obstetrics and Gynecology department organized a very successful expert webinar Innovations in Fetal Therapy. We have published the entire recording of the event online!
Maria Yazdanbakhsh, Professor of Parasitology at the Leiden University Medical Centre (LUMC), has been awarded an ERC Advanced Grant of 2.5 million euros. She will investigate why people in Africa and Southeast Asia respond less to certain vaccines than Europeans. Her goal is to find a solution for low vaccine responses.
Truth be told, the LUMC Global program has been running for a bit more than a year now, but we want to look back at some of our achievements in our slightly more than a year anniversary. Because it has been quite a year for the LUMC Global Initiative in which we have set up multiple projects stimulating international collaboration to work on global health(care) challenges in (bio)medical education and research.